Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Caribou Biosciences, Inc.

CRBU ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.29

▲ +1.57%

Market Cap $138.30M · Vol 387.03K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$138.30M

Micro Cap

Div Yield

N/A

EPS Growth

+36.86%

YoY

RSI (14)

27.27

Momentum

Beta

2.31

vs Market

52W High

$3.53

63.46% below

52W Low

$1.26

2.79% above

Volume

387.03K

Avg 248.41K

P/B

1.24

Price-to-book

ROE

-78.97%

Return on equity

Free Float

91.78%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Caribou Biosciences, Inc. (CRBU) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CRBU pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-17.83%

-18.35%

-19.12%

-31.38%

YTD

-18.87%

-28.33%

-77.99%

-95.57%

Financials & Valuation

TTM · Annual

Total Revenue	$11.16M
Net Income	$-148,125,000.00
Revenue Growth (YoY)	-43.79%
Gross Margin	100.00%
Operating Margin	-1,220.49%
Net Profit Margin	-1,327.40%
ROE	-78.97%
ROA · ROIC	-60.85% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	13.31
P/B	1.24
P/FCF	N/A
EPS Growth	+36.86%
Outstanding Shares	107.21M

Technical Indicators

50-Day SMA	$1.62
200-Day SMA	$1.78
RSI (14)	27.27
Beta	2.31
52-Week High	$3.53
52-Week Low	$1.26

Volume Today	387.03K
Avg Daily Volume (30D)	248.41K
Relative Volume	1.56x
Volatility (10D)	55.08
Volatility (30D)	56.37
Free Float	91.78%

Analyst Consensus

BUY

Current Price $1.29

Mean Target $11.86

52W Low$1.26 52W High$3.53

Current

Target

$1.26 $3.53

Current Analyst target

+819.16% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG008G28LH7

ISINUS1420381089

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.56% ONC BeOne Medicines AG +2.11% 068270.KS Celltrion, Inc. +0.34% ABVX Abivax SA -4.27% ABVX.PA Abivax SA -1.63%

Company Profile

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. The Company is dedicated to developing transformative therapies for patients with devastating diseases. The Company's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that is being evaluated in patients with relapsed or refractory multiple myeloma.